Research programme: anthrax vaccine - Bavarian NordicAlternative Names: MVA-BN Anthrax
Latest Information Update: 09 Oct 2015
At a glance
- Originator Bavarian Nordic
- Class Vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 09 Oct 2015 Discontinued - Preclinical for Anthrax (Prevention) in Germany (Parenteral)
- 17 Dec 2014 Bavarian Nordic has patent protection for MVA-BN® technology in USA and Europe